Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.68 euros per share to Annual Shareholders' Meeting
The Board of Directors of Sartorius Stedim Biotech has proposed a dividend of 0.68 euros per share for fiscal 2020, to be voted on at the Annual General Shareholders' Meeting on March 24, 2021. This proposed dividend represents a total distribution of €62.7 million, a significant increase from last year's dividend of 0.34 euros. Sartorius is a key player in the biopharmaceutical industry, with projected sales revenue of approximately 1,910 million euros for 2020.
- Proposed dividend increase to 0.68 euros per share, up from 0.34 euros, indicating strong financial health.
- Total proposed profit distribution of €62.7 million enhances shareholder returns.
- None.
AUBAGNE, France, Feb. 5, 2021 /PRNewswire/ -- The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today's meeting to submit a proposal to the combined Annual General Shareholders' Meeting on March 24, 2021, to pay a dividend for fiscal 2020 of 0.68 euros per share. Under this proposal, the total distributed profit would be
This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. This is a translation of the original French-language press release. Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation. The original French press release is the legally binding version.
Financial calendar | |
February 18, 2021 | Publication of the 2020 Annual Report |
March 24, 2021 | Virtual Annual Shareholders' Meeting |
April 21, 2021 | Publication of first-quarter figures (January to March 2021) |
July 21, 2021 | Publication of first-half figures (January to June 2021) |
October 20, 2021 | Publication of nine-month figures (January to September 2021) |
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020 the company employed approx. 7,500 people, and earned sales revenue of about 1,910 million euros according to preliminary figures. https://www.sartorius.com/en
Contact
Timo Lindemann
Corporate Communications Spokesman
+49 (0)551.308.4724
timo.lindemann@sartorius.com
https://www.sartorius.com/en
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.
Logo - https://mma.prnewswire.com/media/1123369/Sartorius_Logo.jpg
View original content to download multimedia:http://www.prnewswire.com/news-releases/board-of-directors-of-sartorius-stedim-biotech-resolves-to-propose-dividend-of-0-68-euros-per-share-to-annual-shareholders-meeting-301223172.html
SOURCE Sartorius Stedim Biotech S.A.
FAQ
What is the proposed dividend amount for Sartorius Stedim Biotech in 2021?
When will the Annual General Shareholders' Meeting take place for Sartorius Stedim Biotech?
What was the dividend amount for Sartorius Stedim Biotech in the previous year?
What is the total distribution amount for the proposed dividend by Sartorius Stedim Biotech?
How much sales revenue did Sartorius Stedim Biotech earn in 2020?
